HSBC lifts AstraZeneca target price on haematological cancer forecasts
4th Jan 2016 13:01
(ShareCast News) - HSBC has hiked its target price for AstraZeneca shares after the pharmaceutical giant's acquisition of cancer specialist Acerta Pharma a week before Christmas. AstraZeneca revealed it had agreed to acquire a 55% stake in privately-owned Acerta for $2.5bn, with another $1.5bn due u
Read moreAstraZeneca gout treatment gets FDA approval
23rd Dec 2015 07:12
(ShareCast News) - AstraZeneca said its Zurampic drug, used to treat gout, had received approval from the US Food and Drug Adminstration. Zurampic, also known as Lesinurad, is used in combination with another type of drug that reduces production of uric acid in the body. Sean Bohen, Executive Vice
Read moreNew drug trial data supports AstraZeneca's clinical activity
18th Dec 2015 07:52
(ShareCast News) - AstraZeneca said on Friday that preliminary findings from the ATLANTIC trial of durvalumab, a treatment for a type of non-small cell lung cancer, supports the treatment's clinical activity. The FTSE 100 company said the treatment demonstrated clinical activity and durable response
Read moreThursday newspaper share tips: Dixons Carphone has long-term potential
17th Dec 2015 10:48
(ShareCast News) - Investing in Dixons Carphone is a good long term plan, according to The Times' Tempus. The FTSE 100-listed electronics and travel retailer saw like-for-like revenue rise 5% over the period, to £4.39bn. Its proforma headline profit before tax was also up, 23% to $121m, with statut
Read moreAstraZeneca buys majority stake in Acerta Pharma to expand oncology portfolio
17th Dec 2015 07:08
(ShareCast News) - AstraZeneca has announced it will acquire a 55% stake in Acerta Pharma over its oncology treatment - a deal valued at $4bn (£2.7bn). The deal will give the FTSE 100 pharmaceutical company access to the privately-owned US and Netherlands based biopharmaceutical company's acalabruti
Read moreAstraZeneca to acquire Takeda Pharmaceutical Company for drug rights
16th Dec 2015 07:48
(ShareCast News) - AstraZeneca will acquire the core respiratory business of Takeda Pharmaceutical Company for $575m (£382m). The deal includes the expansion of rights to chronic obstructive pulmonary disease (COPD) treatment roflumilast, also known as Daliresp in the US and Daxas elsewhere. The FT
Read moreAstrazeneca completes disposal of Entocort
15th Dec 2015 15:20
(ShareCast News) - AstraZeneca has received a $380m payment from Irish competitor Perrigo as the FTSE 100 company completed the disposal of right for a Crohn's disease medicine. Perrigo last month agreed to buy the US rights from AstraZeneca to sell Entocort capsules and generic Entocort capsules ma
Read moreAstraZeneca confirms talks with biotech group Acerta
14th Dec 2015 08:14
(ShareCast News) - Pharmaceuticals giant AstraZeneca confirmed that it is exploring potential strategic options with biotech company Acerta Pharma BV. "There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction," AZN said. The statement fol
Read moreBroker tips: IAG, BHP Billiton, AstraZeneca, GSK
2nd Dec 2015 13:11
(ShareCast News) - Clear skies lie ahead for the European Airlines sector going into the winter trading period, thanks to a favourable outlook for capacity growth and given the considerable fall in oil prices since August 2015, Nomura said. The global macroeconomic outlook, notably in the core UK an
Read moreAstraZeneca rallies on double upgrade from Morgan Stanley
2nd Dec 2015 10:00
(ShareCast News) - Pharmaceutical stocks got a boost on Wednesday as Morgan Stanley double upgraded AstraZeneca to 'overweight' from 'underweight' and said it was among its top picks. The bank, which lifted AZN's target price to 5,300p from 4,300p, said it has underperformed dramatically over the pa
Read moreAstraZeneca and Sanofi agree to share chemical compounds
20th Nov 2015 09:29
(ShareCast News) - French and British pharmaceutical giants Sanofi and AstraZeneca have agreed a direct exchange of 210,000 compounds from their respective, proprietary compound libraries. The companies said on Friday that the deal would enhance the chemical diversity of the compound collections and
Read moreFTSE 100 movers: AstraZeneca rival's failure helps boost market
16th Nov 2015 15:12
(ShareCast News) - The FTSE 100 remained resilient after Friday night's terrorist attacks in Paris, with the market up 3.02 points (0.05%) to 6,121.30 points mid-afternoon Monday. AstraZeneca was the market's biggest riser after news that the US Food and Drug Administration has asked for additional
Read moreClovis Oncology tanks as FDA asks for more drug data; AstraZeneca gets a boost
16th Nov 2015 14:28
(ShareCast News) - Shares in Clovis Oncology tanked on Monday after it said the US Food and Drug Administration has requested additional clinical data on the efficacy of its experimental lung cancer drug, rociletinib. The Colorado-based company said it expects the review of this additional informati
Read moreFriday newspaper share tips: Sell as Amec Foster Wheeler faces more pain
6th Nov 2015 11:43
(ShareCast News) - Traders should sell shares in Amec Foster Wheeler as the company prepares for the long haul, according to The Telegraph's Questor. The oil and gas engineering services company announced on Thursday it was cutting its dividend by half and lifting its cost-savings target from £120m
Read moreLondon open: All eyes trained on October US jobs report
6th Nov 2015 08:31
(ShareCast News) - Investors stuck to the sidelines ahead of what some analysts believed would be a make-or-break jobs report for market expectations of a rate hike by the US central bank in December. Ahead of those numbers, as of 0839 GMT the FTSE 100 was advancing by 7.28 points to 6,372.28. The S
Read more